Galcanezumab

證據等級: L5

預測適應症: 3 個

Galcanezumab: From Migraine Prevention to Heparin Cofactor II Deficiency

One-Sentence Summary

Galcanezumab is a humanized monoclonal antibody targeting CGRP (calcitonin gene-related peptide), clinically known for migraine and cluster headache prevention. The TxGNN model predicts possible efficacy in Heparin Cofactor II Deficiency, a rare hereditary coagulation disorder, but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack's own mechanistic analysis finds no known biological link between the two conditions.

Quick Overview

Item	Content
Original Indication	Migraine / cluster headache prevention (from known drug class context; formal indication text not available in this evidence pack)
Predicted New Indication	Heparin Cofactor II Deficiency
TxGNN Prediction Score	99.50%
Evidence Level	L5
Taiwan Market Status	未上市 (Not marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from DrugBank (flagged as a High-severity data gap). Based on the mechanistic rationale included in this evidence pack, galcanezumab is a CGRP-targeting monoclonal antibody: it binds free CGRP and blocks downstream signaling (vasodilation, trigeminovascular sensitization), a pathway relevant to migraine and cluster headache, not to coagulation.

The three TxGNN-predicted indications for this drug — heparin cofactor II deficiency, antithrombin deficiency type 2, and factor V excess with spontaneous thrombosis — are all hereditary coagulation/serpin disorders. According to the evidence pack's own mechanistic analysis, there is no established biological pathway connecting CGRP signaling to thrombin inhibition, serpin structure/function, or coagulation factor expression. No published literature or clinical trial evidence supports any pharmacological interaction between galcanezumab and these disease mechanisms.

In short, this prediction reflects a purely statistical association from the TxGNN knowledge-graph embedding (score 99.50%, rank 5461), with no corroborating mechanistic, preclinical, or clinical evidence. The same conclusion applies to the second- and third-ranked candidates (antithrombin deficiency type 2, factor V excess), both scored similarly (~99.4%) and equally unsupported.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA package insert warnings/contraindications are flagged as a Blocking data gap — required before any Stage 1 safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is at Evidence Level L5 — model output only, with zero clinical trials, zero literature, and no biologically plausible mechanism linking a CGRP-targeting antibody to hereditary coagulation disorders. The drug is also not currently marketed in Taiwan, and core safety data (warnings, contraindications, DDI) are entirely unavailable.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — currently a Blocking gap
Confirmed DrugBank mechanism of action data
Preclinical or mechanistic studies establishing any plausible link between CGRP pathway modulation and coagulation/serpin function
Ongoing monitoring for any future clinical trials or case reports in this disease area before re-evaluating beyond Hold
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.